vimarsana.com

Page 19 - காப்புரிமை பெற்றது மருந்துகள் ஒழுங்குமுறைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Disclosing AI Inventions - Part II: Describing And Enabling AI Inventions - Technology

To print this article, all you need is to be registered or login on Mondaq.com. In Part I of this series on Disclosing AI Inventions, we discussed the basics of machine learning and the unique disclosure challenges presented by the black box nature of trained machine learning models. Nevertheless, current U.S. patent laws are generally viewed as sufficient to ensure adequate disclosure of machine learning inventions to the public, and it will be left to the courts to shape the details of disclosure requirements through interpretation of existing patent laws. In this Part II, we discuss techniques for disclosing machine learning inventions in compliance

Welcome To IANS Live - INTERNATIONAL - Pfizer in talks with India on vax approval, says CEO

Photo Credit: IANS IANSLive New York, May 4 (IANS) Pfizer is discussing expedited approval of its Covid-19 vaccine with the Indian government, company CEO Alber Bourla said while announcing a donation of medicines worth $70 million to fight the resurgent pandemic. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 04-May-2021

Blinken says China acting more aggressively abroad : 60 Minutes interview

Blinken says China acting more aggressively abroad : 60 Minutes interview FILE PHOTO: U.S. Secretary of State Antony Blinken participates in a virtual bilateral meeting with Kenya s President Uhuru Kenyatta during a videoconference at the State Department in Washington, U.S., April 27, 2021. REUTERS/Leah Millis/Pool reuters tickers This content was published on May 3, 2021 - 06:00 May 3, 2021 - 06:00 By David Shepardson WASHINGTON (Reuters) - U.S. Secretary of State Antony Blinken said in an interview that aired on Sunday that China had recently acted more aggressively abroad and was behaving increasingly in adversarial ways. Asked by CBS News 60 Minutes if Washington was heading toward a military confrontation with Beijing, Blinken said: It s profoundly against the interests of both China and the United States to, to get to that point, or even to head in that direction.

Senator Cornyn Considers Expansion Of ITC s Authority Under Section 337 - Intellectual Property

To print this article, all you need is to be registered or login on Mondaq.com. Section 337 of the Tariff Act of 1930, 19 U.S.C. § 1337 ( Section 337 ), gives the U.S. International Trade Commission ( ITC ) broad powers to investigate and address unfair acts and unfair competition in the importation of articles into the United States. Most Section 337 investigations address issues of infringement of statutory intellectual property such as patents, trademarks, and copyrights. Recently, however, Section 337 has increasingly been used to address other unfair acts such as misappropriation of trade secrets, false advertising, breach of contract, and antitrust violations. One primary advantage

iTWire - Nokia ranked as number one in 5G patents

iTWire Thursday, 29 April 2021 20:23 Nokia ranked as number one in 5G patents Shares An independent study by PA Consulting confirms Nokia’s leadership in 5G Standard Essential Patents, and is the latest to rank Nokia number one for patents declared as essential for cellular standards, including 5G. Nokia has announced that it has been ranked as number one in 5G patents in an independent study. The strength of Nokia’s industry leading 5G patent portfolio has once again been confirmed by an independent third party. In its study on Standard Essential Patents (published April 2021), independent analyst firm PA Consulting concluded that Nokia is number one for ownership of granted patents that the researchers found essential to 5G standards.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.